Abstract: Immune checkpoint inhibitors (ICPIs) are a new type of anti-tumor immunotherapy drugs, which activate T cells to eliminate cancer cells by specifically binding to the inhibitory receptors on the surface of T cells, and obtain a good anti-tumor effect. However, a series of immune-mediated or immune-related adverse reactions may occur during the course of treatment, among which skin adverse reactions are the most common. In this paper, the literature of bullous pemphigoid caused by the immune checkpoint inhibitor programmed cell death 1(PD-1) and its ligand programmed cell death ligand 1 (PD-L1) were analyzed retrospectively. To review the prevalence rate, pathogenesis, clinical features, diagnosis and treatment methods.

Key words: pemphigoid, bullous, PD-1 inhibitor, PD-L1 inhibitor, immune-related adverse event